Premium
A new 111 in‐bleomycin complex for combined radiotherapy and chemotherapy
Author(s) -
Hou DeYan,
Hoch Hans,
Johnston Gerald S.,
Tsou K. C.,
Jones Alfred E.,
Farkas Raymond J.,
Miller Elizabeth E.,
Larson Steven M.
Publication year - 1985
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930290206
Subject(s) - bleomycin , medicine , glioma , radiation therapy , transplantation , chemotherapy , nuclear medicine , body weight , kidney , urology , pathology , cancer research
Six days after tumor transplantation three daily intraperitoneal doses of 0.9% NaCl, bleomycin (BLM), or a new 111 In‐bleomycin complex (BLMC, 15 μCi/g body weight) were administered to glioma‐bearing mice. After therapy, tumors in mice treated with 111 In‐BLMC were smaller than those treated with BLM. Sixteen days after the first injection tumor size for 111 In‐BLMC‐treated mice was 560 (240–1,030) mm 3 , 1,980 (1,400–3,290) mm 3 for BLM (P < 0.025), and 4,830 (2,580–9, 180) mm 3 for NaCl (0.1 < P < 0.2). Thirteen days after tumor transplantation glioma‐bearing mice received single intratumor injection of 0.9% NaCl, BLM, or 111 In‐BLMC (1.5 mCi, carried by 0.5 mg BLM/g tumor weight). The average tumor size for 111 In‐BLMC was smaller than that for BLM by a factor of 2.5–3.7. Host weights for these two groups were similar, and morphologic abnormalities were not found in kidney or liver.